Targeted chronic myeloid leukemia therapy: Seeking a cure

American Journal of Health-System Pharmacy

Volumn 64, Issue 24 SUPPL., 2007, Pages

  Fausel, Christopher ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic agents; Dasatinib; Diagnosis; Dosage; Drug interactions; Imatinib mesylate; Leukemia; Mechanism of action; Resistance; Site of action; Toxicity; Transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; ANTIINFECTIVE AGENT; BUSULFAN; CARBOPLATIN; CYTARABINE; CYTARABINE ARABINOSIDE; CYTOCHROME P450; DASATINIB; ETOPOSIDE; HYDROXYUREA; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; QUININE SULFATE; UNCLASSIFIED DRUG;

ARTHRALGIA; BINDING SITE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; EDEMA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROTEIN BINDING; RASH; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 37249091169     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070482     Document Type: Conference Paper

References (18)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.
2. Borgaonkar DS. Philadelphia-chromosome translocation and chronic myeloid leukaemia. Lancet. 1973;1:1250.
3. Stam K, Heisterkamp N, Grosveld G et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med. 1985; 313:1429-33.
4. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84:4064-77.
5. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994; 84:4368-73.
6. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993; 328:593-602.
7. Koziner B, Dengra C, Lucero G et al. Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience. Cancer. 2002; 95:2339-45.
8. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330-40.
9. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346:645-52.
10. Kantarjian H, Talpaz M, Giles F et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913-23.
11. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004.
12. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355:2408-17.
13. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99:1928-37.
14. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99:3530-9.
15. Amadori S, Picardi A, Fazi P et al. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia. 1996; 10:766-8.
16. Deininger MW, O'Brien SG, Ford JM et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003; 21:1637-47.
17. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353:172-187.
18. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354:2531-41.